2 December 2020
  • Share

In December 2020, US company Eat Just were granted regulatory approval by the Singapore Food Agency for the sale of their chicken bites, which are produced by in vitro culture of chicken cells. This is the first time a cultured meat product has been approved for sale, and represents a major milestone for the cellular agriculture movement.

Chicken meat would appear to be an ideal first candidate lab-grown meat to commercialise. It has wide appeal – unlike pork and beef products, there are few cultural taboos associated with eating chicken – and it is familiar to consumers in a variety of different forms, including those closely-resembling Eat Just’s “chicken bites”. Also, taking into account intensive poultry rearing practices, the benefits in terms of animal welfare form a compelling part of the argument in support of cultured chicken meat.

Singapore has long been touted as the likely destination for the first sale of cultured meat products, in view of their progressive attitude to the technology and their proactive approach to establishing the supporting regulatory framework.

Is the future of meat animal-free?

Cellular agriculture is widely recognised as a promising, ethically-sound and more ecologically-friendly means to satisfy the world’s increasing demand for meat. Studies have suggested that lab-grown meat will use a fraction of the land, water and antibiotics used in traditional agricultural practices, and will be associated with dramatically reduced greenhouse gas emissions. Cellular agriculture companies are poised to take a big bite out of the market currently dominated by companies employing traditional animal agricultural practices.

Key technical obstacles to the widespread commercialisation of cultured meat products remain, but solutions to these challenges present commercial opportunities for companies innovating in this space. We expect to see an explosion of patent filings in this area – read more in our forecasting innovation blog.

Find out more about this news story.

Adam is a Partner and Patent Attorney at Mewburn Ellis. He works with biotech companies to build and manage their patent portfolios, drafting patent applications and co-ordinating prosecution worldwide. Adam has particular experience handling portfolios relating to therapeutics (particularly immunotherapies, including adoptive cellular therapies), antibody technology, diagnostics, and regenerative medicine.

Sign up to our newsletter: Forward - news, insights and features

Our People

Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.


Contact Us

We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany.  We’d love to hear from you, so please get in touch.